ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 113 positions · Total reported value $5.22B · Top-10 concentration 43.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2024 13F filing, ORBIMED ADVISORS LLC disclosed 113 equity positions with a combined reported value of $5.22B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 43.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were EWTX ($400.93M), SVA ($340.00M), LLY ($299.09M). By sector, the heaviest allocations are Health Care 84.0%, Industrials 1.0%. Versus the prior quarter, allocation shifted toward Health Care (+4.2pp) and away from Consumer Discretionary (-0.9pp), Other (-2.8pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 73% of names.

The largest new positions opened in Q3 2024 were MBX ($99.04M), UHS ($35.73M), BIOA ($29.61M).

Of the 23 positions fully exited versus the prior quarter, the largest were VRNA ($41.38M), DXCM ($32.87M), HRTX ($22.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • MBX MBX BIOSCIENCES INC COM · $99.04M
  • UHS UNIVERSAL HLTH SVCS INC · $35.73M
  • BIOA BIOAGE LABS INC COM · $29.61M
  • PHAT PHATHOM PHARMACEUTICALS INC · $26.20M
  • CGON CG ONCOLOGY INC COM · $26.08M
  • CRBP CORBUS PHARMACEUTICALS HLDGS COM NEW · $18.83M
  • MEDP MEDPACE HLDGS INC · $14.99M
  • GILD GILEAD SCIENCES INC · $12.72M

Fully Exited (vs previous quarter)

  • VRNA VERONA PHARMA PLC · prev qtr: $41.38M
  • DXCM DEXCOM INC · prev qtr: $32.87M
  • HRTX HERON THERAPEUTICS INC · prev qtr: $22.80M
  • MORF MORPHIC HLDG INC · prev qtr: $20.87M
  • ALXO ALX ONCOLOGY HLDGS INC · prev qtr: $11.42M
  • PGNY PROGYNY INC COM · prev qtr: $7.44M
  • PFE PFIZER INC · prev qtr: $7.00M
  • CATX PERSPECTIVE THERAPEUTICS INC · prev qtr: $4.91M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 84.0%
Other 14.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 15.02M $400.93M 7.68%
7.68%
Hold
2 2.72M $340.00M 6.52%
6.52%
Hold
3 337.60K $299.09M 5.73%
5.73%
Hold
4 3.27M $274.28M 5.26%
5.26%
Hold
5 433.80K $213.11M 4.08%
4.08%
Reduce
6 7.96M $203.29M 3.90%
3.90%
Hold
7 813.00K $157.59M 3.02%
3.02%
Reduce
8 1.32M $149.44M 2.86%
2.86%
Hold
9 782.00K $129.97M 2.49%
2.49%
Reduce
10 344.40K $124.42M 2.38%
2.38%
Add
11 8.29M $120.18M 2.30%
2.30%
Reduce
12 204.50K $110.86M 2.12%
2.12%
Reduce
13 179.00K $104.66M 2.01%
2.01%
Add
14 2.25M $100.53M 1.93%
1.93%
Hold
15 3.81M $99.04M 1.90%
1.90%
New
16 2.32M $93.12M 1.78%
1.78%
Reduce
17 1.79M $87.74M 1.68%
1.68%
Hold
18 687.50K $87.28M 1.67%
1.67%
Hold
19 252.30K $81.29M 1.56%
1.56%
Add
20 5.78M $78.31M 1.50%
1.50%
Hold
21 575.00K $74.75M 1.43%
1.43%
Add
22 3.03M $71.14M 1.36%
1.36%
Hold
23 151.00K $70.23M 1.35%
1.35%
Hold
24 250.30K $68.84M 1.32%
1.32%
Hold
25 7.56M $63.08M 1.21%
1.21%
Reduce
26 1.02M $59.16M 1.13%
1.13%
Reduce
27 1.26M $57.18M 1.10%
1.10%
Reduce
28 106.20K $55.22M 1.06%
1.06%
Reduce
29 1.05M $53.66M 1.03%
1.03%
Reduce
30 84.40K $52.21M 1.00%
1.00%
Reduce
31 73.11M $49.43M 0.95%
0.95%
Hold
32 45.20K $47.52M 0.91%
0.91%
Add
33 679.82K $46.31M 0.89%
0.89%
Add
34 1.39M $44.56M 0.85%
0.85%
Reduce
35 387.00K $44.22M 0.85%
0.85%
Reduce
36 22.36M $41.15M 0.79%
0.79%
Hold
37 766.91K $40.49M 0.78%
0.78%
Reduce
38 1.93M $37.06M 0.71%
0.71%
Hold
39 6.94M $36.66M 0.70%
0.70%
Hold
40 1.27M $36.64M 0.70%
0.70%
Reduce
41 911.42K $35.88M 0.69%
0.69%
Add
42 156.00K $35.73M 0.69%
0.69%
New
43 123.90K $35.60M 0.68%
0.68%
Reduce
44 302.22K $34.82M 0.67%
0.67%
Reduce
45 675.87K $29.87M 0.57%
0.57%
Hold
46 1.42M $29.61M 0.57%
0.57%
New
47 6.06M $27.63M 0.53%
0.53%
Add
48 3.57M $26.76M 0.51%
0.51%
Add
49 1.45M $26.20M 0.50%
0.50%
New
50 691.11K $26.08M 0.50%
0.50%
New

FAQ

What did ORBIMED ADVISORS LLC buy in 2024-Q3?

In its 2024-Q3 13F filing, ORBIMED ADVISORS LLC reported 113 equity positions worth $5.22B in aggregate; its largest disclosed positions were EWTX ($400.93M), SVA ($340.00M), LLY ($299.09M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $5.22B of long equity holdings across 113 positions as of 2024-Q3. Top-10 holdings account for 43.9% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →